Scarica l'app Stockscreener
43.67
1.28%
0.55
Precedente Chiudi:
$43.12
Aprire:
$42.86
Volume 24 ore:
76,951
Relative Volume:
0.56
Capitalizzazione di mercato:
$409.11M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
-6.85%
1M Prestazione:
-7.09%
6M Prestazione:
+21.68%
1 anno Prestazione:
-21.75%
Intervallo 1D:
$42.86
$44.62
Intervallo di 1 settimana:
$41.03
$52.00
Portata 52W:
$30.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Confronta KRRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
43.67 | 409.11M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-21 | Iniziato | Raymond James | Strong Buy |
| 2024-08-14 | Iniziato | William Blair | Outperform |
| 2024-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-10 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Iniziato | Cowen | Outperform |
| 2019-10-28 | Iniziato | Goldman | Buy |
| 2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Wellington Management Group LLP Makes New $436,000 Investment in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com India
Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
100-employee biotech opens new Kendall Square HQ - The Business Journals
Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World
Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro secures approvals in Australia to commence AATD trial of KRRO-110 - Yahoo Finance
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
Korro Bio CFO Vineet Agarwal sells $56,000 in stock By Investing.com - Investing.com South Africa
FMR LLC Reduces Stake in Korro Bio Inc - GuruFocus.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock - Investing.com
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Partners with Novo Nordisk, Reports $169M Cash Position Despite Widening Losses | KRRO Stock News - StockTitan
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
Korro Bio (NASDAQ:KRRO) Stock Price Up 10.9%Here's What Happened - MarketBeat
Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD - BioWorld Online
Korro Bio (NASDAQ:KRRO) Shares Gap DownHere's Why - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Korro Bio Inc Azioni (KRRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):